Selected Publications

  1. Zinc Oxide nanoparticles induce oxidative and proteotoxic stress in ovarian cancer cells and trigger apoptosis independent of p53-mutation status. Padmanabhan A*, Kaushik M, Niranjan R, Richards JS, Ebright, B, Venkatasubbu D*. Applied Surface Science. 2019 Sept; 487-818.                                                                                  *Co-corresponding authors
  2. VCAM1 is induced in ovarian theca and stromal cells in a mouse model of androgen excess. Candeleria NR, Padmanabhan A, Stossi, F, Ljungberg MC, Shelly KE, Pew BK, Solis M, Rossano AM, McAllister JM, Wu S, Richards JS. Endocrinology. 2019 Apr 5
  1. Selective targeting of p53 gain-of-function mutants in cancer. Padmanabhan A. Oncoscience. 2018 Apr 29;5(3-4):73-74.
  2. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Padmanabhan A*, Candeleria N, Wong KK, Nikolai BC, Lonard DM, O’Malley BW, Richards JS. Nature Communications. 2018 Mar 28;9(1):1270.  *Corresponding author
  1. Assembly of an evolutionarily conserved alternative proteasome isoform in human cells. Padmanabhan A, Vuong SA, Hochstrasser M. Cell Reports. 2016 Mar 29;14(12):2962-74.
  2. Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants. Padmanabhan A*, Rao V*, De Marzo AM, Bieberich CJ. Prostate. 2016 May; 76(6):523-33.                                        *Equal contribution
2013 and Earlier
  1. Assembly Protein kinase A regulates MYC protein through transcriptional and post-translational mechanisms in a catalytic subunit isoform-specific manner. Padmanabhan A, Li X, Bieberich CJ. Journal of Biological Chemistry. 2013 May 17;288(20):14158-69.
  2. Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. Padmanabhan A, Gosc EB, Bieberich CJ. Journal of Cellular Biochemistry. 2013 May; 114(5):1050-7.
  3. MYC, metabolism and malignancy: Opportunities for therapeutic intervention. Padmanabhan A. Journal of Carcinogenesis and Mutagenesis. 2013; 4 (146), 1480-1489.
  4. Protein Kinase CK2 controls the stability of prostate derived ETS factor. Chisholm C, Padmanabhan A, Guan B, Li X, Kalra S, Bieberich CJ. The Open Cancer Journal. 2010; 3, 109-115.
  5. The reverse in-gel kinase assay to profile physiological kinase substrates. Li X, Guan B, Srivastava MK, Padmanabhan A, Hampton BS, Bieberich CJ. Nature Methods. 2007 Nov:4(11):957-62.​